Judge Says Lilly Lacks Standing in Copycat Obesity Drug Suit (1)

Eli Lilly & Co. failed to prove in a federal court that a business selling copycat versions of its obesity drug causes harm to its company and consumers, dealing a blow to the drugmaker’s aggressive fight against the compounding industry.

The company failed to plausibly allege that it has Article III standing to assert its claims against Mochi Health Corp., a telehealth company that connects consumers with physicians that can prescribe compounded versions of Lilly’s tirzepatide, Judge Jacqueline Scott Corley for the US District Court for the Northern District of California said in an order filed Oct. 24.

Lilly is ...